Skip to content

Study · Randomized controlled trial · n = 106 · 2018

5 results

The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest.

Wiberg S, Kjaergaard J, Schmidt H, Thomsen JH, Frydland M, Winther-Jensen M, Lindholm MG, Høfsten DE, Engstrøm T, Køber L, Møller JE, Hassager C

Critical care medicine1 Feb 2018Cited by 10 (Europe PMC)

PMID29189347 (opens in a new tab)DOI10.1097/ccm.0000000000002814 (opens in a new tab)PepBankPUB-29189347
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In comatose cardiac arrest patients, exenatide accelerated blood glucose decline versus placebo during the first 6 hours.

    In plain wordsIn comatose cardiac arrest patients, blood glucose decreased faster with exenatide than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBlood glucose clearance
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).

    Measurements

    Faster glucose decline
    17%
    versus placebo
    Faster glucose decline, 95% CI
    8.9 to 25%
    versus placebo

    Source sentences

    Summary
    During the first 6 hours from study drug initiation, the levels of blood glucose and lactate decreased 17% (95% CI, 8.9-25%; p = 0.0004) and 21% (95% CI, 6.0-33%; p = 0.02) faster in patients receiving exenatide versus placebo, respectively.
    2 context sentences
    Summary · context
    Consecutive sample of adult, comatose patients undergoing targeted temperature management after out-of-hospital cardiac arrest from a presumed cardiac cause, irrespective of the initial cardiac rhythm.
    Summary · context
    Patients were randomized 1:1 to receive 6 hours and 15 minutes of infusion of either 17.4 μg of the glucagon-like peptide-1 analog exenatide (Byetta; Lilly) or placebo within 4 hours from sustained return of spontaneous circulation.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In comatose cardiac arrest patients, exenatide accelerated lactate decline versus placebo during the first 6 hours.

    In plain wordsIn comatose cardiac arrest patients, lactate decreased faster with exenatide than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLactate clearance
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).

    Measurements

    Faster lactate decline
    21%
    versus placebo
    Faster lactate decline, 95% CI
    6 to 33%
    versus placebo

    Source sentences

    Summary
    During the first 6 hours from study drug initiation, the levels of blood glucose and lactate decreased 17% (95% CI, 8.9-25%; p = 0.0004) and 21% (95% CI, 6.0-33%; p = 0.02) faster in patients receiving exenatide versus placebo, respectively.
    2 context sentences
    Summary · context
    Consecutive sample of adult, comatose patients undergoing targeted temperature management after out-of-hospital cardiac arrest from a presumed cardiac cause, irrespective of the initial cardiac rhythm.
    Summary · context
    Patients were randomized 1:1 to receive 6 hours and 15 minutes of infusion of either 17.4 μg of the glucagon-like peptide-1 analog exenatide (Byetta; Lilly) or placebo within 4 hours from sustained return of spontaneous circulation.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In comatose cardiac arrest patients, exenatide increased heart rate compared with placebo.

    In plain wordsIn comatose cardiac arrest patients, exenatide increased heart rate compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHeart rate
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).

    Measurements

    Heart rate difference
    ≈ 10 beats per minute
    versus placebo

    Source sentences

    Summary
    Exenatide increased heart rate by approximately 10 beats per minute compared to placebo (p < 0.0001).
    2 context sentences
    Summary · context
    Consecutive sample of adult, comatose patients undergoing targeted temperature management after out-of-hospital cardiac arrest from a presumed cardiac cause, irrespective of the initial cardiac rhythm.
    Summary · context
    Patients were randomized 1:1 to receive 6 hours and 15 minutes of infusion of either 17.4 μg of the glucagon-like peptide-1 analog exenatide (Byetta; Lilly) or placebo within 4 hours from sustained return of spontaneous circulation.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In comatose cardiac arrest patients, exenatide did not affect mean arterial pressure versus placebo.

    In plain wordsIn comatose cardiac arrest patients, exenatide did not change mean arterial pressure compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMean arterial pressure
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).

    Source sentences

    Summary
    There was no effect of exenatide on other hemodynamic variables.
    3 context sentences
    Summary · context
    The effects of exenatide were examined on the following prespecified covariates within the first 6 hours from study drug initiation: lactate level, blood glucose level, heart rate, mean arterial pressure, and combined dosage of norepinephrine and dopamine.
    Summary · context
    Consecutive sample of adult, comatose patients undergoing targeted temperature management after out-of-hospital cardiac arrest from a presumed cardiac cause, irrespective of the initial cardiac rhythm.
    Summary · context
    Patients were randomized 1:1 to receive 6 hours and 15 minutes of infusion of either 17.4 μg of the glucagon-like peptide-1 analog exenatide (Byetta; Lilly) or placebo within 4 hours from sustained return of spontaneous circulation.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In comatose cardiac arrest patients, exenatide did not affect combined norepinephrine and dopamine dosage versus placebo.

    In plain wordsIn comatose cardiac arrest patients, exenatide did not change the combined dosage of blood pressure drugs compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCombined norepinephrine and dopamine dosage
    Study

    n = 106

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    17.4 μg · infusion · 6 hours and 15 minutesAs given in this study (human).

    Source sentences

    Summary
    There was no effect of exenatide on other hemodynamic variables.
    3 context sentences
    Summary · context
    The effects of exenatide were examined on the following prespecified covariates within the first 6 hours from study drug initiation: lactate level, blood glucose level, heart rate, mean arterial pressure, and combined dosage of norepinephrine and dopamine.
    Summary · context
    Consecutive sample of adult, comatose patients undergoing targeted temperature management after out-of-hospital cardiac arrest from a presumed cardiac cause, irrespective of the initial cardiac rhythm.
    Summary · context
    Patients were randomized 1:1 to receive 6 hours and 15 minutes of infusion of either 17.4 μg of the glucagon-like peptide-1 analog exenatide (Byetta; Lilly) or placebo within 4 hours from sustained return of spontaneous circulation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02442791

GLP-1 Analogs for Neuroprotection After Cardiac Arrest

Jesper Kjaergaardn = 120Jun 2014 to Jun 2016

Cardiac Arrest · Coma

Trial pageClinicalTrials.govUpdated 28 Sept 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.